Glenn Killingworth has been appointed vice president of Business Development at PCI Synthesis, Inc. Mr. Killingworth will work to drive business growth through the development and implementation of PCI’s sales and marketing strategy, as well as build and lead business development teams for PCI in both existing and new markets worldwide.
 
Mr. Killingworth is specialist in the field of organic chemistry and brings 25 years of experience working for companies including Fisher Scientific, Peakdale Molecular, Almac Sciences, WuXi Apptec and Asymchem. He has spent the last decade in commercial and business development roles, and has a proven track record of sales achievements principally in the pharmaceutical R&D sector worldwide.
 
“Glenn’s two decades of industry experience, including his track record in growing markets in Europe and the U.S., will be an important addition to PCI’s senior management team. His success with emerging and mid-sized pharmaceutical companies in Europe, as well as in the U.S., will help the company continue its growth,” said Ed Price, president of PCI Synthesis. “We’ve spent the past 18 months improving our organization, and the addition of Glenn is an important investment in our capabilities.”